Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia

生物仿制药 医学 临床试验 药效学 人口 内科学 药代动力学 环境卫生
作者
Aleksandr Petrov,И. Е. Макаренко,Bella Belova,Anait Levonovna Melikyan,Valeria B. Saparova,Kirill V. Peskov,Nataliya Kudryashova,Vladislav V. Kovalik,Maria Gefen,Alexandr Khokhlov,Драй Роман Васильевич
出处
期刊:Clinical pharmacology in drug development [Wiley]
卷期号:14 (2): 116-126 被引量:1
标识
DOI:10.1002/cpdd.1494
摘要

During biosimilar drug development, conducting a clinical trial of biosimilar efficacy in patients may become necessary in the presence of residual uncertainty regarding the biosimilarity of the drugs. In the development of the biosimilar romiplostim GP40141, we aimed to use a model-based in silico clinical trial (ISCT) approach to optimize the planned biosimilar efficacy trial in patients with immune thrombocytopenia. The population pharmacokinetic/pharmacodynamic model for healthy volunteers was modified and validated to describe platelet dynamics in patients with immune thrombocytopenia. ISCTs were then conducted using the modified model for various expected scenarios of biosimilar efficacy trials. Statistical analysis of the simulation results was subsequently used to confirm the appropriateness of the chosen design for evaluating the planned efficacy end points. Since the planned trial includes both patients naïve to therapy with thrombopoietin receptor agonists and nonnaïve patients, various expected ratios of naïve to nonnaïve patients (1:1, 1:2, 1:3) and the percentage of nonnaïve patients who previously received eltrombopag (0% or 30%) were assessed across 200 ISCTs performed for each scenario. The obtained estimates of empirical power for the equivalence test of platelet response/durable platelet response by the 10th/26th week between the test and reference groups were not less than 94%, regardless of the scenario. Differences in power between the 10- and 26-week end points did not exceed 4%. The analysis of ISCT results allowed for an effective reduction of uncertainty in the biosimilar development of GP40141, demonstrating the appropriateness of using the 10-week efficacy end point as the primary one.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
小橘子发布了新的文献求助10
1秒前
洛枝发布了新的文献求助10
2秒前
飘逸的星星完成签到,获得积分10
2秒前
Hello的应助被无辜的笑蓝采纳,获得10
3秒前
4秒前
4秒前
吃葡萄不吐葡萄皮的应助被FG采纳,获得10
5秒前
5秒前
zcyuqing发布了新的文献求助10
6秒前
lili完成签到 ,获得积分10
7秒前
桐桐的应助被YANG采纳,获得10
9秒前
9秒前
卡皮巴拉完成签到,获得积分10
9秒前
10秒前
thq发布了新的文献求助10
10秒前
刘zy完成签到,获得积分10
11秒前
zb完成签到,获得积分10
12秒前
Ava的应助被甜甜十三采纳,获得10
12秒前
13秒前
null的应助被馥郁采纳,获得10
14秒前
爆米花的应助被洛枝采纳,获得10
14秒前
绿叶发布了新的文献求助10
14秒前
yzy发布了新的文献求助10
15秒前
NIIER完成签到,获得积分10
15秒前
MQL完成签到,获得积分10
15秒前
15秒前
16秒前
16秒前
丘比特的应助被弘毅采纳,获得10
16秒前
熄灯完成签到,获得积分10
17秒前
18秒前
19秒前
20秒前
cc1完成签到,获得积分10
20秒前
Yexin发布了新的文献求助10
21秒前
null的应助被熄灯采纳,获得10
22秒前
22秒前
甜甜十三完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153573
求助须知:如何正确求助?哪些是违规求助? 9550279
关于积分的说明 21697424
捐赠科研通 7742161
什么是DOI,文献DOI怎么找? 3425546
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469181